Bank of America Corp DE Sells 2,238,388 Shares of Cerus Corporation (NASDAQ:CERS)

Bank of America Corp DE cut its position in Cerus Corporation (NASDAQ:CERS - Free Report) by 94.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 124,042 shares of the biotechnology company's stock after selling 2,238,388 shares during the quarter. Bank of America Corp DE owned about 0.07% of Cerus worth $191,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently bought and sold shares of CERS. BNP Paribas Financial Markets raised its position in shares of Cerus by 13.5% in the fourth quarter. BNP Paribas Financial Markets now owns 206,472 shares of the biotechnology company's stock worth $318,000 after buying an additional 24,575 shares in the last quarter. Ameriprise Financial Inc. bought a new position in Cerus in the 4th quarter worth about $40,000. Jane Street Group LLC raised its holdings in shares of Cerus by 37.6% in the 4th quarter. Jane Street Group LLC now owns 409,408 shares of the biotechnology company's stock valued at $630,000 after acquiring an additional 111,858 shares in the last quarter. Northern Trust Corp boosted its position in shares of Cerus by 1.2% during the 4th quarter. Northern Trust Corp now owns 1,634,780 shares of the biotechnology company's stock valued at $2,518,000 after acquiring an additional 18,878 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its holdings in shares of Cerus by 17.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 234,277 shares of the biotechnology company's stock worth $361,000 after purchasing an additional 34,694 shares in the last quarter. 78.37% of the stock is owned by institutional investors.

Cerus Trading Down 7.1%

Shares of Cerus stock traded down $0.10 during trading on Tuesday, hitting $1.31. 842,752 shares of the stock traded hands, compared to its average volume of 1,306,773. The firm's fifty day moving average is $1.33 and its 200-day moving average is $1.54. Cerus Corporation has a 52 week low of $1.12 and a 52 week high of $2.54. The company has a debt-to-equity ratio of 1.15, a current ratio of 2.32 and a quick ratio of 1.63.

Cerus (NASDAQ:CERS - Get Free Report) last issued its earnings results on Thursday, May 1st. The biotechnology company reported ($0.04) EPS for the quarter, topping analysts' consensus estimates of ($0.05) by $0.01. Cerus had a negative net margin of 10.23% and a negative return on equity of 34.81%. The company had revenue of $43.24 million for the quarter, compared to analysts' expectations of $47.44 million. As a group, equities research analysts predict that Cerus Corporation will post -0.08 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $4.00 target price on shares of Cerus in a research note on Friday, February 21st.

About Cerus

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.